Moneycontrol PRO
HomeNewsPfizer

At Moneycontrol, the Results page helps you effectively track corporate announcements and results for various listed companies across both India and abroad. With our Results page, you can keep abreast with an updated, comprehensive view of all the profit/loss statements, company spendings, AGM outcomes, and quarterly and annual results from all these listed companies. Additionally, Moneycontrol also regularly tracks international MNCs listed on NASDAQ and Asian bourses, including popular companies like Apple, Google, Alibaba. Apart from finding solid copies of company results, stock movements consequent to these company results, expectations, and analytical post results copies, you will also find copies and articles detailing the earnings, impact, and all major announcements made to media/exchanges by these companies, so that you do not miss anything. We also provide you with concrete data points to help you spot profitable trades, stock build-ups, and bulk deals. At Moneycontrol, we also cover analysts/investors meetings; scrutinise results and data and BSE/NSE reports or news. The copies are not just full of information and data, but are also adequately supplemented with expert views, investor opinions, extensive interviews, videos, and a huge variety of explainers, analyses, and informative slideshows to help you gauge the market and make investment decisions in the best possible manner. More

Jump to
  • Pfizer Q2 PAT seen up 8.4% to Rs 78.3 cr: Centrum

    Net Sales are expected to increase by 8.1 percent Q-o-Q (up 5.8 percent Y-o-Y) to Rs 542 crore, according to Centrum.

  • Pfizer Q1 net up 6% at Rs 80 cr

    Pfizer Q1 net up 6% at Rs 80 cr

    Drug firm Pfizer today reported a 6.47 per cent rise in standalone net profit to Rs 80.04 crore for the quarter ended June 30.

  • Earnings Pataka: Lakshmi Machine Works solid set of Q3 results

    Earnings Pataka: Lakshmi Machine Works solid set of Q3 results

    CNBC-TV18‘s Varinder Bansal gets you companies that have stood out in terms of outstanding Q3 numbers. The stocks on his radar for today are Lakshmi Machine Works, Pfizer & La Opala.

  • Pharma companies revenues to rise 12% in Q3: Anand Rathi

    Pharma companies revenues to rise 12% in Q3: Anand Rathi

    Pharma companies are likely to post 12 percent Y-o-Y revenue growth. However, excluding Wockhardt (FDA issues) and Fortis Healthcare (divestments), revenue growth is expected to be 19 percent Y-o-Y.

  • Looking at insulin biz to drive growth ahead: Biocon

    Looking at insulin biz to drive growth ahead: Biocon

    Kiran Mazumdar Shaw, CMD of Biocon said their branded formulation business has grown 45 percent and excluding it the bio pharma business has seen 20 percent growth year-on-year. She also feels the business is gaining traction in emerging markets and the US.

  • Pfizer plans to launch 15 new products in FY13

    Pfizer plans to launch 15 new products in FY13

    Pharma major Pfizer registered a net profit of Rs 48.10 crore in the fourth quarter of FY12 in comparison to Rs 63.14 crore in the corresponding quarter last fiscal.

  • Biocon Q4 net up 25%, divests stake in German unit

    Biocon Q4 net up 25%, divests stake in German unit

    India's largest listed biotechnology firm Biocon said on Thursday it would divest its stake in German unit AxiCorp, after roughly meeting estimates with a 25% rise in the fourth-quarter net profit.

  • Business to grow Rs 1000cr in FY11: Stride Arcolab

    Business to grow Rs 1000cr in FY11: Stride Arcolab

    Stride Arcolab announced it Q3 results for FY11. The company reported a consolidated net profit of Rs 122.4 crore for the year ended 2010 as against Rs 109.7 crore in previous year.

  • Have multiple launches planned in 2011, says Pfizer

    Have multiple launches planned in 2011, says Pfizer

    Speaking to CNBC-TV18, Kewal Handa, MD of Pfizer said the firm has planned multiple launches in 2011. "We expect to grow above market rates," he added.

  • Pfizer Dec qtr PAT seen up 17.3% at Rs 49.9cr: Emkay

    Pfizer Dec qtr PAT seen up 17.3% at Rs 49.9cr: Emkay

    Emkay Global Financial Services has come out with its earning estimates on pharma sector for the quarter ended December 2010. According to the research firm, Pfizer December quarter sales are expected to go up by 11.1% to Rs 227.5 crore, Year-on-Year, (Y-o-Y) basis.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347